产品说明书

(R)-Lansoprazole

Print
Chemical Structure| 138530-94-6 同义名 : 右兰索拉唑 ;Dexlansoprazole;T-168390;TAK-390;(+)-Lansoprazole
CAS号 : 138530-94-6
货号 : A414150
分子式 : C16H14F3N3O2S
纯度 : 98%
分子量 : 369.361
MDL号 : MFCD13196699
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(284.27 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • Proton Pump
描述 (R)-Lansoprazole is the R enantiomer of Lansoprazole. Lansoprazole (AG 1749) is an orally active proton pump inhibitor that suppresses gastric acid production. Additionally, Lansoprazole (AG 1749) is a potent brain-penetrating inhibitor of neutral sphingomyelinase (N-SMase), which also acts as an exosome inhibitor[1][2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00274339 Laryngopharyngeal Reflux Not Applicable Unknown June 2008 United States, Kentucky ... 展开 >> Commonwealth Ear, Nose & Throat Recruiting Louisville, Kentucky, United States, 40207 Contact: Marti Gardner, MSN    502-893-0159 ext 1185    mgardner@commonwealthent.com    Principal Investigator: Kenneth M Hodge, MD          Sub-Investigator: John R Morris, MD          Sub-Investigator: Donald V Welsh, MD          Sub-Investigator: Gorden T McMurry, MD          Sub-Investigator: Andrew R Gould, MD          Sub-Investigator: Keith D Forwith, PhD, MD          Sub-Investigator: Steven D Shotts, MD          Sub-Investigator: Tamalynn O'Daniel, MSN, ARNP          Sub-Investigator: Jolene H Boswell, PA-C          Sub-Investigator: Mary S McLaughlin, PA-C          Sub-Investigator: Martha L Gardner, MSN, ARNP          Sub-Investigator: Brian Walker, PA-C 收起 <<
NCT02297126 Adverse Drug Reaction Not Applicable Completed - United States, Indiana ... 展开 >> Eskenazi Health System Indianapolis, Indiana, United States, 46250 收起 <<
NCT00237679 Voice Disorders ... 展开 >> Gastroesophageal Reflux 收起 << Not Applicable Terminated(Terminated due to f... 展开 >>unding loss.) 收起 << - United States, Wisconsin ... 展开 >> University of Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.54mL

2.71mL

1.35mL

27.07mL

5.41mL

2.71mL
参考文献

[1]Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.

[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

[3]M Miura, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8.